Do you want to read an article? Please log in or register.
Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial
Further Publications
Related content
Retinal Diseases
Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial
Ophthalmology.
van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF
doi: 10.1016/j.ophtha.
Retinal Diseases
RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4
Retina
van Rijssen TJ, Hahn LC, van Dijk EHC, Tsonaka R, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, Keunen JEE, MacLaren RE, Querques G, Fauser S, Downes SM, Hoyng CB, Boon CJF
doi: 10.1097/IAE.0000000000003157
COMMENTED
Retinal Diseases
The Effect of Selective Retina Therapy with Automatic Real-Time Feedback-Controlled Dosimetry for Chronic Central Serous Chorioretinopathy: A Randomized, Open-Label, Controlled Clinical Trial
★ 1
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
J Clin Med
Lee JY, Kim MH, Jeon SH, Lee SH, Roh YJ
doi: 10.3390/jcm10194295
COMMENTED
Retinal Diseases
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial
★ 2
Recommended and commented by
Prof. Dr emer. Josef Flammer, Faculty Member
★ 3
Recommended by
Dr Katarzyna Konieczka, Faculty Member
★ 3
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Lancet.
Lotery A, Sivaprasad S, O'Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC, VICI trial investigators
doi: 10.1016/S0140-6736(19)32981-2.
Retinal Diseases
Cross-over to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy
Am J Ophthalmol.
van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, Tsonaka R, MacLaren RE, Downes SM, Fauser S, Boon CJF, Hoyng CB
doi: 10.1016/j.ajo.2020.04.007.
Retinal Diseases
Photodynamic therapy in combination with intravitreal ziv-aflibercept and aflibercept injection in patients with chronic or repeatedly recurrent acute central serous chorioretinopathy: a single-center retrospective study
Clin Ophthalmol.
Doepfner JM, Michels S, Graf N, Becker MD, Freiberg FJ
doi: 10.2147/OPTH.S165199.
Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy
JAMA Ophthalmol.
van Dijk EH, Schellevis RL, van Bergen MG, Breukink MB, Altay L, Scholz P, Fauser S, Meijer OC, Hoyng CB, den Hollander AI, Boon CJ, de Jong EK
doi: 10.1001/
Retinal Diseases
Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy
Front Pharmacol
Fasler K, Gunzinger JM, Barthelmes D, Zweifel SA
doi: 10.3389/fphar.2021.675295
COMMENTED
Retinal Diseases
Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience
Br J Ophthalmol.
Petkovsek DS, Cherfan DG, Conti FF, Hom GL, Ehlers JP, Babiuch AS, Rachitskaya AV, Kaiser PK, Schachat AP, Srivastava SK, Sharma S, Singh RP
doi: 10.1136/bjophthalmol-2019-314047.